United States v. Abbott Laboratories

• Court: District Court, S.D. California
• Decided: April 24, 2025
• Docket: 3:20-cv-00286
• Status: Unknown

Opinion

2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 UNITED STATES OF AMERICA, et al. ex rel. Case No.: 20cv286-W (MSB) Everest Principals, LLC, 12 ORDER GRANTING DEFENDANTS’ Plaintiffs, 13 MOTION TO COMPEL DISCOVERY v. 14 [ECF NO. 154] ABBOTT LABORATORIES, et al., 15 Defendants. 16 17 18 This is a qui tam case, wherein Plaintiff-Relator, Everest Principals, LLC (“Relator”) 19 maintains causes of action against Defendants Abbott Laboratories, Abbott Laboratories 20 Inc., Abbott Cardiovascular Systems Inc., and Abbott Vascular Inc. (collectively referred 21 to as “Defendants” or “Abbott”) on behalf of the United States of America (“United 22 States”) and several states for violations of the federal False Claims Act (“FCA”) and 23 analogous state laws. (See ECF No. 85 at 6.) 24 Now pending before this Court is the parties’ briefing regarding Relator’s 25 response to Defendants’ Interrogatory No. 3. (See ECF Nos. 154 & 155.) In short, the 26 parties disagree about whether Relator should be required to provide a complete list of 27 allegedly false claims during the fact discovery period. (Id.) After reviewing informal 2 Relator to supplement its response to Defendants’ Interrogatory No. 3 by producing a 3 complete list of allegedly false claims no later than May 16, 2025, with leave for 4 Defendants to conduct additional fact discovery on any newly identified claims after the 5 fact discovery cutoff. Following the conference, Relator requested an opportunity for 6 formal briefing, and the parties agreed to file contemporaneous briefs setting forth their 7 respective positions on April 18, 2025. (See ECF No. 151.) For the reasons explained 8 below, the Court GRANTS Defendants’ Motion to Compel. 9 I. BACKGROUND 10 A. Factual Background 11 Relator is a limited liability company whose sole member was employed by 12 Defendants as a Therapy Development Specialist in its Structural Heart Division from 13 August 2015 to April 2017. (See ECF No. 85 at 7.) Defendants are involved in the 14 manufacturing and sale of medical devices, instruments, medications, and other health 15 care products. (Id. at 8.) In the operative Third Amended Complaint (“Operative 16 Complaint”), Relator summarizes its allegations as follows: “Defendants engaged in an 17 unlawful, systematic, and nationwide scheme of paying kickbacks to physicians and 18 hospitals in the form of, inter alia, patient referrals, patient practice building, free 19 patient marketing service, honoraria for sham speaker programs, rewards in the form of 20 clinical trial opportunities, marketing events and consulting services, free lavish meals, 21 and cocktail parties, to induce physicians and hospitals to use Abbott’s [cardiac medical 22 device] for medical procedures performed on cardiac patients covered by [federal and 23 state] healthcare programs, in violation of the FCA, [Anti-Kickback Statute (“AKS”)], and 24 analogous state laws and statutes.” (Id. at 6–7.) 25 B. Procedural History 26 Relator filed the original Complaint on February 14, 2020. (ECF No. 1.) After the

27 United States reported that all named government entities declined to intervene in the 2 alleging causes of action on behalf of the United States and twenty-seven states, plus 3 the District of Columbia. (ECF No. 35 at 6.) Defendants again moved to dismiss, arguing 4 Relator failed to adequately allege presentment of a false claim, inducement of a false 5 claim, causation with particularity, illegal kickbacks, and scienter related to the federal 6 claims, and that the state law claims should be dismissed. (ECF No. 45 at 13–32.) The 7 District Court found Relator’s allegations sufficient for its federal claims, but dismissed 8 the state law claims for failure to allege “with particularity how any false claims were 9 submitted to each state identified in the FAC.” (ECF No. 56 at 16.) 10 Relator filed a Second Amended Complaint (“SAC”) on September 22, 2022, 11 maintaining the federal claims and state law claims on behalf of twenty-five states and 12 the District of Columbia. (ECF No. 57 at 6.) Defendants moved to dismiss the state law 13 claims in the SAC, arguing Relator failed to state claims on which relief could be granted 14 due to a lack of particularity. (ECF No. 59 at 12–21.) The District Court dismissed all 15 state law FCA claims except for those pertaining to four states: California, Florida, 16 Georgia, and New York. (ECF No. 62 at 4–9.) The District Court found Relator had 17 sufficiently pleaded FCA claims in violation of these four states’ laws. (Id.) Finally, 18 Plaintiffs filed the Operative Complaint on May 23, 2023. (ECF No. 85.) 19 II. INSTANT DISCOVERY DISPUTE 20 A. Defendants’ Interrogatory No. 3 and Relator’s Responses 21 Defendants served Interrogatory No. 3 on Relator on August 14, 2023. (See ECF 22 No. 154-5 at 3–4.) It asked Relator to: 23 Identify each alleged false claim (as that term is used in the Complaint) that You allege Abbott presented or caused to be presented to either a federal 24 or state government. 25 (Id. at 3.) Relator timely objected to Interrogatory No. 3 as a premature contention 26 interrogatory, “to the extent it seeks information outside the control, custody, and 27 possession” of Relator, and “to the extent it seeks information to be provided by 2 2024, Relator promised to supplement its responses “once it receives claims data from 3 [the Centers for Medicare and Medicaid Services (“CMS”)].” (ECF No. 154-7 at 3–4.) 4 From August 26, 2024, to October 7, 2024, the federal government produced 5 claims data. (See ECF No. 154-2 at 3.) Additionally, Georgia produced claims data on 6 August 28, 2024; New York produced claims data on October 15, 2024; and California 7 produced claims data on November 19, 2024. (Id.) To date, Florida is the only relevant 8 state that has not produced claims data. (See ECF No. 154-1 at 8.) On February 24, 9 2025, Defendants requested the complete response to Interrogatory No. 3, noting that 10 “Relator has now been in receipt of the CMS claims data for more than four months but 11 has not yet supplemented its response.” (ECF No. 154-8 at 2.) On March 7, 2025, 12 Relator responded that it “never agreed to supplement its response prior to the Court- 13 ordered expert discovery deadline.” (ECF No. 155-4 at 2.) Nevertheless, Relator agreed 14 to supplement its response by March 21, 2025, and said it “will further supplement its 15 response through its expert reports.” (Id.) 16 Accordingly on March 21, 2025, Relator provided its supplemental response and 17 shared “an initial list of Medicare Part B false claims that it has identified to date.” (ECF 18 No. 154-3 at 3.) Relator again noted it “will further supplement its Response in 19 connection with its expert reports.” (Id. at 4.) An accompanying Excel spreadsheet 20 listed 3,773 allegedly false claims. (See ECF No. 154-4.) 21 On March 28, 2025, Defendants sent correspondence arguing Relator’s March 21, 22 2025, supplemental response was deficient. (See ECF No. 154-9.) Specifically, Abbott 23 argued it would be “severely prejudiced if Relator fails to identify the entire set of 24 allegedly false claims in fact discovery” because it needed sufficient time to conduct 25 factual investigation on the claims at issue. (Id. at 4.) Relator responded on March 31, 26 2025, noting its disagreement. (See ECF No. 154-10.) The parties then brought the

27 dispute before the Court for an informal discovery conference on April 10, 2025. (ECF 2 Defendants seek to compel Relator’s production of a complete list of the allegedly 3 false claims by the close of fact discovery (May 16, 2025), with leave for Defendants to 4 conduct fact discovery beyond this deadline “if Relator identifies any claims in addition 5 to the 3,773 that Relator has already identified.” (ECF No. 154-1 at 2.) Defendants say 6 that Interrogatory No. 3 “goes to the very heart of this False Claims Act case: the 7 allegedly false claims that Relator maintains were submitted to the government.” (Id.) 8 First, Defendants argue that identification of allegedly false claims during fact discovery 9 is standard in FCA cases like this one. (Id. at 5–7.) Next, Defendants contend that 10 because Relator has already identified nearly 4,000 claims, it has effectively conceded 11 that its response to Interrogatory No. 3 does not require an expert report. (Id. at 7.) 12 Additionally, Defendants assert expert discovery is too late, as Abbott needs time 13 to investigate and challenge the supposedly false claims via fact discovery. (Id.) “[I]f 14 Relator waits until expert discovery to identify the rest of the claims at issue, then 15 Abbott could suddenly find itself litigating another 10,000 claims” or more and 16 Defendants would have no recourse through fact discovery. (Id.) Defendants argue 17 they should have the opportunity to ask about allegedly false claims during Relator’s 18 upcoming deposition, and Defendants should similarly be able to seek information from 19 third parties about specific false claims. (Id. at 8.) Defendants contend Relator should 20 not be excused from timely identifying the false claims based on Florida’s delay, while 21 the federal government and the other three states have produced claims data. (Id.) 22 In response, Relator asserts there is “well-established precedent recognizing that 23 the identification of false claims routinely requires expert analysis,” particularly in FCA 24 cases involving voluminous medical claims. (ECF No. 155 at 2–4, 9–11.) Relator says the 25 claims data at issue is so complex that it “requires expertise just to process and 26 interpret.” (Id. at 2.) Further, Relator questions why Defendants waited until two

27 months before the close of fact discovery to assert that Relator must identify every 2 identification of false claims during expert discovery does not mean Defendants are not 3 without recourse, as they can use rebuttal experts to respond to testimony concerning 4 the identification of false claims. (Id. at 4.) 5 Moreover, Relator argues Defendants are using this dispute to prematurely 6 “narrow the universe of false claims and the damages at issue . . . with complete 7 prejudice to any supplementation following fact discovery.” (Id.) Relator contends 8 Defendants have not identified any cases supporting the proposition that relators must 9 identify all allegedly false claims during fact discovery. (Id. at 6–9.) In sum, Relator 10 requests the Court set aside its tentative ruling and deny Defendants’ Motion to Compel 11 because it argues there is no legal or procedural basis for requiring identification of 12 every false claim without expert analysis. (Id. at 11.) If the Court is inclined to maintain 13 its tentative, Relator requests the Court do the following: (1) extend the deadline to 14 identify false claims until June 30, 2025—the current expert reports deadline; (2) allow 15 Defendants only thirty days to conduct fact discovery regarding false claims; and (3) 16 extend all expert deadlines for a corresponding period of seventy-five days. (Id.) 17 III. APPLICABLE LAW 18 The Federal Rules of Civil Procedure1 authorize parties to obtain discovery 19 regarding any unprivileged matter that is relevant to any claim or defense and 20 proportional to the needs of the case, “considering the importance of the issues at stake 21 in the action, the amount in controversy, the parties’ relative access to relevant 22 information, the parties’ resources, the importance of the discovery in resolving the 23 issues, and whether the burden or expense of the proposed discovery outweighs its 24 likely benefit.” Fed. R. Civ. P. 26(b)(1). District courts have broad discretion to 25 determine relevancy for discovery purposes. See Hallett v. Morgan, 296 F.3d 732, 751 26

27 2 the discovery sought is “unreasonably cumulative or duplicative, or can be obtained 3 from some other source that is more convenient, less burdensome, or less expensive”; 4 the requesting party “has had ample opportunity” to obtain discovery; or the discovery 5 sought is beyond the scope of Rule 26(b)(1). Fed. R. Civ. P. 26(b)(2)(C). 6 The Rules provide that an interrogatory “may relate to any matter that may be 7 inquired into under Rule 26(b).” Fed. R. Civ. P. 33(a)(2). Further, “[a]n interrogatory is 8 not objectionable merely because it asks for an opinion or contention that relates to 9 fact or the application of law to fact.” Id. If a responding party objects, “[t]he grounds 10 for objecting to an interrogatory must be stated with specificity.” Fed. R. Civ. P. 11 33(b)(4). Any interrogatory not objected to must be answered “fully in writing under 12 oath.” Fed. R. Civ. P. 33(b)(3). Under Rule 37, a party may move the Court to compel 13 disclosure or discovery. See Fed. R. Civ. P. 37(a)(1). The party seeking discovery must 14 demonstrate that the request satisfies Rule 26’s relevance requirement. See, e.g., 15 Ogeone v. United States, No. CV 13-00166 SOM-RLP, 2014 WL 12611289, at *1 (D. Haw. 16 Oct. 14, 2014); Soto v. City of Concord, 162 F.R.D. 603, 610 (N.D. Cal. 1995). The party 17 resisting discovery “has the burden of clarifying, explaining, and supporting its 18 objections.” DIRECTV, Inc. v. Trone, 209 F.R.D. 455, 458 (C.D. Cal. 2002) (citing, inter 19 alia, Blankenship v. Hearst Corp., 519 F.2d 418, 429 (9th Cir. 1975)). 20 IV. DISCUSSION 21 The instant disagreement is essentially about the appropriate timeline for this 22 discovery. Defendants insist that Relator must provide a complete, unqualified 23 response to Interrogatory No. 3 during fact discovery. (ECF No. 154-1.) Relator retorts 24 that it should not be required to identify all allegedly false claims without the benefit of 25 expert analysis. (ECF No. 155.) 26 As a preliminary matter, the Court finds the information requested in

27 Interrogatory No. 3—i.e., the allegedly false claims “Abbott presented or caused to be 2 believes support the allegations in its Operative Complaint. See, e.g., United States ex 3 rel. Dougherty v. Guild Mortg. Co., No. 16cv2909-JAH (BLM), 2020 WL 3542391, at *5 4 (S.D. Cal. June 30, 2020) (collecting cases where courts found that “interrogatories 5 directing a plaintiff to state facts supporting contentions in his complaint are ‘entirely 6 appropriate’”) (internal citations omitted). 7 Additionally, the Court finds the requested list of allegedly false claims is factual 8 information that should be produced during fact discovery. As Defendants point out, 9 Relator produced an Excel spreadsheet listing 3,773 allegedly false claims on March 21, 10 2025. (ECF No. 154-1 at 4; ECF No. 154-4.) At the informal discovery conference on 11 April 10, 2025, Relator’s counsel explained this spreadsheet only covers those false 12 claims that Relator has personal knowledge about. Relator argues given the sheer 13 complexity of the claims data, experts are needed to identify the remaining false claims. 14 (See generally ECF No. 155.) However, even if expertise is needed, Relator has not 15 explained why its experts have not made sufficient progress on this work, considering it 16 began receiving claims data in August 2024. (ECF No. 154-2 at 3.) As of November 19, 17 2024, Relator had received claims data from the federal government and three out of 18 four states involved in this case. (Id.) The only claims data yet to be produced is from 19 the state of Florida. (ECF No. 154-1 at 8.) 20 While it undoubtedly takes time to sort through voluminous medical claims data, 21 Relator has possessed most of this material for more than five months. Moreover, this 22 case has been pending for more than five years, and discovery has been open since April 23 2023. (See ECF Nos. 1 & 77.) The Court has granted four extensions of the case 24 schedule on (1) November 17, 2023; (2) April 23, 2024; (3) October 4, 2024; and (4) 25 January 22, 2025. (ECF Nos. 120, 132, 137, 147.) In total, the fact discovery deadline 26 has been continued 500 days, from January 2, 2024, to May 16, 2025, and the expert

27 discovery deadline has been continued 528 days, from May 14, 2024, to October 24, 2 with or without the assistance of experts. 3 In similar discovery disputes, other courts have routinely granted motions to 4 compel this type of information during fact discovery. In Dougherty, another FCA case 5 in this district, the relevant interrogatory asked the government to “[i]dentify all claims 6 which you purport to be false or fraudulent covered by this lawsuit, including . . . [t]he 7 specific reason or reasons you purport the claims were false.” United States ex rel. 8 Dougherty v. Guild Mortg. Co., No. 16cv2909-JAH (BLM), 2020 WL 3542391, at *3 (S.D. 9 Cal. June 30, 2020). The court rejected the government’s contention that the 10 interrogatory should not be answered “until after fact discovery ends and expert 11 discovery begins,” emphasizing that discovery had been open for approximately seven 12 months at the time. Id. at *5. In the instant case, Interrogatory No. 3 seeks less 13 information—only the identity of the allegedly false claims, rather than the identity and 14 reasons the claims were false. (See ECF No. 154-5 at 3.) Additionally, discovery has 15 been open for longer, as almost exactly two years have passed since the Court entered 16 its original Scheduling Order on April 18, 2023. (ECF No. 77.) 17 Likewise in Fesenmaier, the court compelled the government to identify specific 18 false claims, reasoning such information was relevant to Defendants’ valuation of the 19 case and the damages calculation. United States v. Cameron-Ehlen Grp., Inc., No. 13- 20 CV-3003 (WMW/DTS), 2019 WL 1453063, at *3–4 (D. Minn. Apr. 2, 2019), aff’d sub 21 nom. United States ex rel. Fesenmaier v. Cameron-Ehlen Grp., Inc., No. 13-CV-3003 22 (WMW/DTS), 2019 WL 3245003 (D. Minn. July 19, 2019). Although the court only 23 required the government to respond “to the extent of its current knowledge,” it said 24 any supplementation must be completed forty-five days before the close of discovery. 25 Id. at *4. Here, the Court tentatively ordered Relator to provide a complete list of 26 allegedly false claims by the close of fact discovery on May 16, 2025, and said

27 supplementation would be left to the discretion of the District Court. Given the 2 Relator has possessed most claims data since November 2024 or earlier—the Court 3 finds this timing to be reasonable. In fact, in Vision Quest, the court compelled 4 identification of false claims six months before the close of fact discovery. See United 5 States v. Vision Quest Indus., Inc., No. 2:21-cv-05197-FLA-PDx, 2022 WL 21826111, at 6 *1–2, *11 (C.D. Cal. Feb. 3, 2022). Thus, requiring Relator to provide a list of the specific 7 false claims by the close of fact discovery is appropriate at this stage of the proceedings. 8 Many of the cases that Relator cites are unavailing. For example, in Poehling, the 9 court denied a motion to compel further response to an interrogatory that asked 10 defendant to do the following: “with respect to every diagnosis code on the 11 government’s list, (a) identify which code is supported by a medical record and (b) 12 identify every medical record review that [defendant] conducted.” United States ex rel. 13 Poehling v. United Health Grp., Inc., No. CV 16-8697 FMO (SSX), 2021 WL 9763051, at *1 14 (C.D. Cal. May 28, 2021). Notably, the government had already identified a list of 15 twenty-eight million codes. Id. at *2. The court determined expert analysis was needed 16 to provide a reliable answer to the interrogatory, which required a comparison of 17 twenty-eight million codes to more than twenty million medical records. Id. By 18 contrast, Interrogatory No. 3 asks Relator to simply identify the universe of false claims, 19 rather than answer questions about the false claims. (ECF No. 154-5 at 3.) 20 Relator highlights several other cases to support its proposition that experts are 21 needed to identify the false claims in this matter. (See ECF No. 155 at 9–10 (citing, inter 22 alia, United States v. Reliance Med. Sys., LLC, No. CV1406979DDPJCX, 2022 WL 524062, 23 at *2 (C.D. Cal. Feb. 22, 2022); United States v. SuperValu, Inc., No. 11-3290, 2019 WL 24 1277031, at *1 (C.D. Ill. Mar. 20, 2019); United States v. Teva Pharms. USA, Inc., No. 13 25 CIV. 3702 (CM), 2019 WL 1245656, at *24 (S.D.N.Y. Feb. 27, 2019); United States v. 26 Halifax Hosp. Med. Ctr., No. 6:09-CV-1002-ORL-31, 2013 WL 6017329, at *9 (M.D. Fla.

27 Nov. 13, 2013).) The Court finds these non-binding cases are distinguishable from the 1 number of claims at issue, but there is no indication the court assessed when during the 2 || discovery process the false claims should be identified. 2022 WL 524062, at *2. 3 || Likewise, SuperValu involved a motion to exclude expert testimony, but the court did 4 ||not address the appropriate timeline for identification of false claims. 2019 WL 5 ||1277031, at *1. Ultimately, Relator has not explained why it cannot identify all allegedly 6 || false claims by May 16, 2025, despite receiving significant extensions to the discovery 7 ||schedule and obtaining most claims data by November 2024. 8 V. CONCLUSION 9 For the reasons discussed in this Order, the Court confirms its tentative ruling and 10 || GRANTS Defendants’ Motion to Compel. (ECF No. 154.) The Court ORDERS Relator to 11 || supplement its response to Interrogatory No. 3 by producing a complete list of allegedly 12 || false claims no later than May 16, 2025. Defendants may conduct fact discovery on any 13 || newly identified false claims by June 16, 2025. Supplementation after May 16, 2025, 14 || will be left to the discretion of the District Court. 15 IT IS SO ORDERED. 16 ||Dated: April 24, 2025 = _ 2 FF 18 Honorable Michael S. Berg United States Magistrate Judge 19 20 21 22 23 24 25 26 27 28